SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [06/26/2025 16:30 PDT] SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), Up By 100% ($1.7) From $1.7 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/26/2025 10:29 PDT] SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), Up By 100% ($1.67) From $1.67 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/25/2025 16:12 PDT] SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), Up By 100% ($1.58) From $1.58 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/24/2025 07:29 PDT] SLS Expected to Trade Up After Bullish Patterns Develop
• [06/16/2025 07:11 PDT] SLS Expected to Trade Up After Bullish Patterns Develop
• [06/05/2025 07:09 PDT] SLS Expected to Trade Up After Bullish Patterns Develop
• [06/04/2025 07:14 PDT] SLS Expected to Trade Up After Bullish Patterns Develop
• [05/21/2025 10:30 PDT] SELLAS Life Sciences Group, Inc. (NASDAQ:SLS), Up By 100% ($1.76) From $1.76 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [05/20/2025 07:37 PDT] SLS Expected to Trade Up After Bullish Patterns Develop